CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,242 | -21.4% | 115,514 | -2.8% | 0.01% | -12.5% |
| Q2 2023 | $6,671 | +19.2% | 118,852 | -4.0% | 0.01% | +14.3% |
| Q1 2023 | $5,598 | +12.6% | 123,789 | +1.2% | 0.01% | 0.0% |
| Q4 2022 | $4,973 | -100.0% | 122,355 | -45.8% | 0.01% | -68.2% |
| Q3 2022 | $14,750,000 | -8.1% | 225,724 | -14.5% | 0.02% | 0.0% |
| Q2 2022 | $16,050,000 | +47.7% | 264,127 | +52.5% | 0.02% | +69.2% |
| Q1 2022 | $10,870,000 | +9.7% | 173,187 | +32.4% | 0.01% | +18.2% |
| Q4 2021 | $9,913,000 | +52.0% | 130,818 | +124.5% | 0.01% | +57.1% |
| Q3 2021 | $6,521,000 | -27.5% | 58,263 | +4.9% | 0.01% | -30.0% |
| Q2 2021 | $8,989,000 | +9462.8% | 55,529 | +7074.3% | 0.01% | – |
| Q1 2021 | $94,000 | -27.7% | 774 | -8.9% | 0.00% | – |
| Q4 2020 | $130,000 | +106.3% | 850 | -43.3% | 0.00% | – |
| Q1 2020 | $63,000 | – | 1,498 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |